NCT06292169 Pectoralis Minor Release Versus Non-release in RSA
| NCT ID | NCT06292169 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Reverse Total Shoulder Arthroplasty |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-08-07 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2024-08-07 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to assess if concomitant open pectoralis minor release would improve pain and outcomes after Reverse Shoulder Arthroplasty (RSA). The main questions it aims to answer are: * whether releasing the pectoralis minor prophylactically could have better pain relief * whether releasing the pectoralis minor prophylactically could have increased Range of motion (ROM) outcomes * whether releasing the pectoralis minor prophylactically could have higher final Patient Reported Outcome Measurements (PROMs) Participants will be randomized to either undergo RSA with pectoralis minor release or RSA without pectoralis minor release.
Eligibility Criteria
Inclusion Criteria: * All patients undergoing surgery for reverse total shoulder arthroplasty * Patients willing and able to provide informed consent Exclusion Criteria: * Revision arthroplasty * Reverse shoulder arthroplasty for proximal humerus fractures * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners
Contact & Investigator
Eric Wagner, MD
PRINCIPAL INVESTIGATOR
Emory University
Frequently Asked Questions
Who can join the NCT06292169 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Reverse Total Shoulder Arthroplasty. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06292169 currently recruiting?
Yes, NCT06292169 is actively recruiting participants. Contact the research team at eric.r.wagner@emory.edu for enrollment information.
Where is the NCT06292169 trial being conducted?
This trial is being conducted at Atlanta, United States, Atlanta, United States.
Who is sponsoring the NCT06292169 clinical trial?
NCT06292169 is sponsored by Emory University. The principal investigator is Eric Wagner, MD at Emory University. The trial plans to enroll 90 participants.